Articles Insights From the Experts at Teiko Learn about the latest advances in immune profiling from Teiko’s team of scientific experts. All Topics Analytical Validation Blood Collection Customer Spotlight Educational Webinar Expert Interview Immune Profiling Mass Cytometry Technology Technical Webinar Uncategorized Rapid Onsite Fixation of Human Whole Blood Samples with Teiko’s Two-Step TokuKit for Clinical Trials In this live webinar, we’ll guide you through a full demo of the TokuKit, covering every step from blood draw to kit processing and storage at -80°C. Read Article I have an informatics team. Why do I need you? Teiko saves your scientists time and effort by streamlining data processing and analysis, ensuring organized and reliable results. Our advantage is we knit all the pieces together: specimen collection, tracking, panels, report validation, and data delivery. In data delivery, we provide an analytical pipeline that transforms complex cytometry data into actionable insights. Read Article 13 markers should be good enough for my flow panel, right? “I have a 13 marker panel that analyzes T-cells. And my drug just hit the T-cells, why bother looking at any other immune cell types, like B cells, or NK cells? Even if those other cells are affected, I don’t know how to interpret those results.” The reason is: those extra subsets might predict the difference between success and failure for a drug. Read Article Pre-fixation versus post-fixation: what’s the difference? Read Article How many cells do you need to reliably detect a population of interest? The answer to this common question is more complex than you’d think. We use real-world examples to break down how reliability depends on the confidence you need, the variability you can accept, and of course the frequency of the population you’re interested in measuring. Read Article TokuProfile Web 2.0 Launch: Live in Action In this live webinar, Carlos Medina, Director of Product Management, and Will Chronister, Senior Computational Scientist, demonstrate how to use the the newly redesigned TokuProfile Web to answer key questions using real-world customer data. Read Article How are your antibodies validated? How are our mass cytometry antibodies validated? We discuss how we pair the best of software design with expert scientist intuition to select the best clone, concentration, and cellular condition for each antibody on our panel. Read Article CLIA Validation Data for Teiko Bio’s Mass Cytometry Immune Profiling Assay for PBMCs In this live webinar, Ramji Srinivasan, cofounder and CEO of Teiko Bio, will walk through the precision and stability data for our mass cytometry assay for pan-immune profiling of PBMCs isolated from healthy human clinical samples. Read Article Whole Blood or PBMCs for immune profiling? Dr. Jolien Sweere discusses data from a technical validation experiment performed by Teiko Bio showing how mass cytometry immune profiling data from whole blood compares to data from PBMCs. Read Article Discovery of immune-related adverse event associations in metastatic melanoma Ramji Srinivasan, cofounder and CEO of Teiko Bio, shares original research on blood-based biomarkers of immune-related adverse events in metastatic melanoma performed by Teiko scientists in collaboration with Dr. Siwen Hu-Lieskovan of Huntsman Cancer Institute. Read Article What looking beyond the tumor microenvironment has taught us about immunotherapy Dr. Jolien Sweere walks us through scientific publications showing that immune responses outside the tumor are necessary for effective immunotherapy. Read Article Accelerating therapeutic discovery in blood cancer We highlight six recent key discoveries made using mass cytometry across a wide range of blood cancers including AML ALL, lymphoma, and myeloma. Read Article Video Webinar: Immune responses to cancer immunotherapy outside the tumor Where do T cells get activated after cancer immunotherapy? Matthew Spitzer, PhD, reviews current literature and his lab’s recent Cell publication in this educational webinar. Read Article Understanding the immune setpoint – a new approach to cancer treatment Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy. Read Article What the Costco hot dog teaches us about our immune system What the Costco hotdog and soda deal and inflation can teach us about better understanding the immune system. Read Article Customer Spotlight: Shernan Holtan, MD Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling. Read Article The complementary capabilities of single-cell RNA seq and high-dimensional cytometry Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings. Read Article Peripheral blood analysis is key to developing effective cancer immunotherapies Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline. Read Article Flow vs. Spectral vs. Mass Cytometry: What’s the difference? What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development. Read Article Five things to look for in an immune profiling partner Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner. Read Article
Rapid Onsite Fixation of Human Whole Blood Samples with Teiko’s Two-Step TokuKit for Clinical Trials In this live webinar, we’ll guide you through a full demo of the TokuKit, covering every step from blood draw to kit processing and storage at -80°C. Read Article
I have an informatics team. Why do I need you? Teiko saves your scientists time and effort by streamlining data processing and analysis, ensuring organized and reliable results. Our advantage is we knit all the pieces together: specimen collection, tracking, panels, report validation, and data delivery. In data delivery, we provide an analytical pipeline that transforms complex cytometry data into actionable insights. Read Article
13 markers should be good enough for my flow panel, right? “I have a 13 marker panel that analyzes T-cells. And my drug just hit the T-cells, why bother looking at any other immune cell types, like B cells, or NK cells? Even if those other cells are affected, I don’t know how to interpret those results.” The reason is: those extra subsets might predict the difference between success and failure for a drug. Read Article
How many cells do you need to reliably detect a population of interest? The answer to this common question is more complex than you’d think. We use real-world examples to break down how reliability depends on the confidence you need, the variability you can accept, and of course the frequency of the population you’re interested in measuring. Read Article
TokuProfile Web 2.0 Launch: Live in Action In this live webinar, Carlos Medina, Director of Product Management, and Will Chronister, Senior Computational Scientist, demonstrate how to use the the newly redesigned TokuProfile Web to answer key questions using real-world customer data. Read Article
How are your antibodies validated? How are our mass cytometry antibodies validated? We discuss how we pair the best of software design with expert scientist intuition to select the best clone, concentration, and cellular condition for each antibody on our panel. Read Article
CLIA Validation Data for Teiko Bio’s Mass Cytometry Immune Profiling Assay for PBMCs In this live webinar, Ramji Srinivasan, cofounder and CEO of Teiko Bio, will walk through the precision and stability data for our mass cytometry assay for pan-immune profiling of PBMCs isolated from healthy human clinical samples. Read Article
Whole Blood or PBMCs for immune profiling? Dr. Jolien Sweere discusses data from a technical validation experiment performed by Teiko Bio showing how mass cytometry immune profiling data from whole blood compares to data from PBMCs. Read Article
Discovery of immune-related adverse event associations in metastatic melanoma Ramji Srinivasan, cofounder and CEO of Teiko Bio, shares original research on blood-based biomarkers of immune-related adverse events in metastatic melanoma performed by Teiko scientists in collaboration with Dr. Siwen Hu-Lieskovan of Huntsman Cancer Institute. Read Article
What looking beyond the tumor microenvironment has taught us about immunotherapy Dr. Jolien Sweere walks us through scientific publications showing that immune responses outside the tumor are necessary for effective immunotherapy. Read Article
Accelerating therapeutic discovery in blood cancer We highlight six recent key discoveries made using mass cytometry across a wide range of blood cancers including AML ALL, lymphoma, and myeloma. Read Article
Video Webinar: Immune responses to cancer immunotherapy outside the tumor Where do T cells get activated after cancer immunotherapy? Matthew Spitzer, PhD, reviews current literature and his lab’s recent Cell publication in this educational webinar. Read Article
Understanding the immune setpoint – a new approach to cancer treatment Matthew Spitzer, Associate Professor at UCSF and scientific cofounder of Teiko Bio, explains how understanding each patient’s individual “immune setpoint” could be the key to maximizing cancer treatment efficacy. Read Article
What the Costco hot dog teaches us about our immune system What the Costco hotdog and soda deal and inflation can teach us about better understanding the immune system. Read Article
Customer Spotlight: Shernan Holtan, MD Dr. Shernan Holtan discusses her research into a pregnancy hormone that may hold the key to treating life-threatening graft-vs-host diseases and how Teiko helped her overcome the barriers to high-dimensional immune profiling. Read Article
The complementary capabilities of single-cell RNA seq and high-dimensional cytometry Researchers have used scRNAseq and CyTOF as complementary tools in a wide variety of published studies to provide additional breadth, depth, and coverage when analyzing cellular processes. Here are a few specific examples that illustrate the diversity and range of these approaches in a variety of biomedical research settings. Read Article
Peripheral blood analysis is key to developing effective cancer immunotherapies Although most research focuses on tumor-killing immune cells at the site of the tumor, new research increasingly demonstrates the value of studying circulating immune cells in peripheral blood to identify new therapeutic targets to enhance tumor-killing immune responses. We highlight recent publications with peripheral blood biomarkers and discuss recommendations for how to incorporate peripheral blood immune profiling into your drug development pipeline. Read Article
Flow vs. Spectral vs. Mass Cytometry: What’s the difference? What’s the difference between flow, spectral, and mass cytometry? We highlight the differences between these three different cytometry platforms used by drug developers to characterize the immune system so you can determine which platform provides you the richest information to advance your research and therapeutic development. Read Article
Five things to look for in an immune profiling partner Make the most of your time and resources by choosing an immune profiling partner who can advance your oncology, autoimmune, or infectious disease pipelines. Here are five things to look for when evaluating an immune profiling partner. Read Article